Literature DB >> 16000587

Enhanced nectin-1 expression and herpes oncolytic sensitivity in highly migratory and invasive carcinoma.

Zhenkun Yu1, Mei-Ki Chan, Pornchai O-charoenrat, David P Eisenberg, Jatin P Shah, Bhuvanesh Singh, Yuman Fong, Richard J Wong.   

Abstract

PURPOSE: Although a variety of malignant tumors are susceptible to therapy with oncolytic herpes simplex viruses, the determinants of tumor sensitivity to these viruses are poorly understood. Nectin-1 is a cell surface adhesion molecule that is a component of intercellular adherens junctions and also functions as a herpes viral receptor. Because highly invasive cells may have decreased intercellular adhesion, we sought to determine if such cells might also have altered availability of cell surface nectin-1 to act as a herpes receptor. EXPERIMENTAL DESIGN AND
RESULTS: A series of squamous cell carcinoma lines of increasing migratory and invasive potential, termed MG1-MG14, were selected by serial passages of murine SCC7 through Matrigel invasion chambers. Available cell surface nectin-1 was enhanced on the MG11 and MG14 cell lines in comparison to SCC7 as measured by cellular ELISA and immunofluorescence microscopy. A replication-competent, oncolytic herpes virus (NV1023) showed an increased ability to enter MG11 and MG14 cells as compared with SCC7 cells. Furthermore, MG11 and MG14 supported increased herpes viral replication and cytotoxicity over SCC7. For all three of the cell lines, viral entry assays revealed that the actively migrating cells were significantly more susceptible to herpes infection than the nonmigrating cells.
CONCLUSIONS: These results show that malignant cells with highly migratory and invasive properties may exhibit increased cell surface nectin-1 availability, which may serve as a herpes viral receptor to enhance the efficacy of herpes oncolytic therapy. This finding has implications regarding patient selection for future clinical trials using these promising therapeutic vectors.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16000587     DOI: 10.1158/1078-0432.CCR-05-0309

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  23 in total

1.  Pharmacy Operationalization of the Intralesional Oncolytic Immunotherapy Talimogene Laherparepvec.

Authors:  Ali McBride; John Valgus; Sandeep Parsad; Erica M Sommermann; Robert Nunan
Journal:  Hosp Pharm       Date:  2018-01-10

2.  Epithelial-mesenchymal transition enhances response to oncolytic herpesviral therapy through nectin-1.

Authors:  Chun-Hao Chen; Wei-Yi Chen; Shu-Fu Lin; Richard J Wong
Journal:  Hum Gene Ther       Date:  2014-04-02       Impact factor: 5.695

3.  Hypoxia Moderates γ(1)34.5-Deleted Herpes Simplex Virus Oncolytic Activity in Human Glioma Xenoline Primary Cultures.

Authors:  Gregory K Friedman; Marilyn C Haas; Virginia M Kelly; James M Markert; George Yancey Gillespie; Kevin A Cassady
Journal:  Transl Oncol       Date:  2012-06-01       Impact factor: 4.243

Review 4.  Animal models and molecular imaging tools to investigate lymph node metastases.

Authors:  Elliot L Servais; Christos Colovos; Adam J Bograd; Julie White; Michel Sadelain; Prasad S Adusumilli
Journal:  J Mol Med (Berl)       Date:  2011-05-10       Impact factor: 4.599

Review 5.  The Role of Oncolytic Viruses in the Treatment of Melanoma.

Authors:  Claire-Audrey Y Bayan; Adriana T Lopez; Robyn D Gartrell; Kimberly M Komatsubara; Margaret Bogardus; Nisha Rao; Cynthia Chen; Thomas D Hart; Thomas Enzler; Emanuelle M Rizk; Jaya Sarin Pradhan; Douglas K Marks; Larisa J Geskin; Yvonne M Saenger
Journal:  Curr Oncol Rep       Date:  2018-08-25       Impact factor: 5.075

6.  Expressions of connexin and par-3 in the distal margin of rectal cancer after ultra-low anterior resection.

Authors:  Jun Liu; Weikang Zhang; Jinlin Liu; Xiaoming Lu; Yaoping Long; Yancai Zhou; Shenghong Liu
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2009-06-10

7.  Nectin-2 and DDX3 are biomarkers for metastasis and poor prognosis of squamous cell/adenosquamous carcinomas and adenocarcinoma of gallbladder.

Authors:  Xiongying Miao; Zhu-Lin Yang; Li Xiong; Qiong Zou; Yuan Yuan; Jinghe Li; Lufeng Liang; Meigui Chen; Senlin Chen
Journal:  Int J Clin Exp Pathol       Date:  2013-01-15

Review 8.  Herpes simplex virus oncolytic therapy for pediatric malignancies.

Authors:  Gregory K Friedman; Joseph G Pressey; Alyssa T Reddy; James M Markert; G Yancey Gillespie
Journal:  Mol Ther       Date:  2009-04-14       Impact factor: 11.454

9.  Engineered herpes simplex viruses efficiently infect and kill CD133+ human glioma xenograft cells that express CD111.

Authors:  Gregory K Friedman; Catherine P Langford; Jennifer M Coleman; Kevin A Cassady; Jacqueline N Parker; James M Markert; G Yancey Gillespie
Journal:  J Neurooncol       Date:  2009-06-12       Impact factor: 4.130

10.  A novel molecular interaction for the adhesion of follicular CD4 T cells to follicular DC.

Authors:  Kent S Boles; William Vermi; Fabio Facchetti; Anja Fuchs; Timothy J Wilson; Thomas G Diacovo; Marina Cella; Marco Colonna
Journal:  Eur J Immunol       Date:  2009-03       Impact factor: 5.532

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.